Métodos para avaliar a qualidade fisiológica de sementes de arroz

Aiming to evaluate the efficiency of different methods to determine the physiological quality of rice seeds, two groups of 10 lots each of the varieties BR-IRGA 409 and BR-IRGA 410 were used. Seed quality was determined through seed water content, weight of 1,000 seeds, germination and vigor tests: first germination counting, classification of seedling vigor, accelerated aging, modified cold test, seedling growth and weight and field emergence. It was concluded that the modified cold test and classification of seedling vigor are capable of stratifying different rice samples according to their vigor and are positively correlated with field emergence. The accelerated aging, under 42'C and 100% relative humidity of air conditions stratifies the samples in relation to seed vigor. The tests of seedling growth and weight, when eliminating abnormal seedlings and non-germinated seeds, are not capable of stratifying rice seed samples as a function of seed vigor.Com o objetivo de avaliar a eficiência de diferentes métodos para a determinação da qualidade fisiológica de sementes de arroz, foram utilizados dois grupos de dez lotes de sementes, das variedades BR-IRGA 409 e BR-IRGA 410. A qualidade dos lotes foi determinada através do teor de água, peso de mil sementes, teste de germinação e dos testes de vigor: primeira contagem de germinação, classificação do vigor de plântulas, envelhecimento acelerado, teste de frio modificado, tamanho e massa seca de plântulas e emergência no campo. Concluiu-se que os testes de frio modificado e classificação do vigor de plântulas são capazes de estratificar diferentes lotes de arroz pelo vigor e se correlacionam positivamente com a emergência no campo. O teste de envelhecimento acelerado, sob as condições de 42'C e 100% de umidade relativa do ar, durante 120 horas, estratifica lotes de arroz , em função do vigor das sementes. Os testes de tamanho e massa seca de plântulas, quando eliminam as plântulas anormais e sementes não germinadas, não são capazes de estratificar lotes de sementes de arroz, em função do vigor

Efeito do tratamento com fontes de zinco e boro na germinação e vigor de sementes de milho

The experiment was carried during the period of march 1992 to november 1992, to study the effects of maize seed treatment with zinc, boron and pesticides, on the germination and vigour during storage. The experimental design was a complete randomized 3x2x6 fatorial with four replicátions. The treatments were three storage periods (zero, four and eight month), pesticides treatments with or without, and six sources of zinc and boron (control, Zn-Biocrop, B-Biocrop, Organic-B, Zn-Biocrop -I- B-Biocrop and Zn-Biocrop + Organic-B), in the dose 2.50g of the Zn and 0.l5g of the B/kg of seeds. The results show that Zn-Biocrop maintain high germination and vigour for eight month of storage. The boron treatment (B-Biocrop and Organic-B) showed a low germination and vigour.Foi conduzido um experimento no Departamento de Fitotecnia da Universidade Federal de Santa Maria, RS, no período de março a novembro de 1992, com o objetivo de verificar o efeito da aplicação de fontes de zinco e boro em sementes de milho tratadas ou não com defensivos agrícolas. Adotou-se o esquema fatorial 3x2x6, em delineamento inteiramente casualizado, com quatro repetições. Os tratamentos constaram de avaliações em três épocas (logo após o tratamento, quatro e oito meses depois), utilização de sementes de milho com e sem tratamento fítossanitário, combinados com seis fontes de zinco e boro (testemunha, Zn-Biocrop, B-Biocrop, E-Orgânico, Zn-Biocrop + B-Biocrop e Zn-Biocrop + B-Orgânico), nas doses únicas de 2,50g Zn e de 0,15g B/kg de sementes. Os resultados obtidos mostram que a aplicação da fonte Zn-Biocrop não prejudica a germinação e o vigor, pelo período de oito meses de armazenamento. O tratamento de sementes com boro (B-Biocrop e B-Orgânico) diminui a germinação e o vigor

Tracking development assistance for health and for COVID-19 : a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990-2050

Background The rapid spread of COVID-19 renewed the focus on how health systems across the globe are financed, especially during public health emergencies. Development assistance is an important source of health financing in many low-income countries, yet little is known about how much of this funding was disbursed for COVID-19. We aimed to put development assistance for health for COVID-19 in the context of broader trends in global health financing, and to estimate total health spending from 1995 to 2050 and development assistance for COVID-19 in 2020. Methods We estimated domestic health spending and development assistance for health to generate total health-sector spending estimates for 204 countries and territories. We leveraged data from the WHO Global Health Expenditure Database to produce estimates of domestic health spending. To generate estimates for development assistance for health, we relied on project-level disbursement data from the major international development agencies' online databases and annual financial statements and reports for information on income sources. To adjust our estimates for 2020 to include disbursements related to COVID-19, we extracted project data on commitments and disbursements from a broader set of databases (because not all of the data sources used to estimate the historical series extend to 2020), including the UN Office of Humanitarian Assistance Financial Tracking Service and the International Aid Transparency Initiative. We reported all the historic and future spending estimates in inflation-adjusted 2020 US$, 2020 US$ per capita, purchasing-power parity-adjusted US$per capita, and as a proportion of gross domestic product. We used various models to generate future health spending to 2050. Findings In 2019, health spending globally reached$8. 8 trillion (95% uncertainty interval [UI] 8.7-8.8) or $1132 (1119-1143) per person. Spending on health varied within and across income groups and geographical regions. Of this total,$40.4 billion (0.5%, 95% UI 0.5-0.5) was development assistance for health provided to low-income and middle-income countries, which made up 24.6% (UI 24.0-25.1) of total spending in low-income countries. We estimate that $54.8 billion in development assistance for health was disbursed in 2020. Of this,$13.7 billion was targeted toward the COVID-19 health response. $12.3 billion was newly committed and$1.4 billion was repurposed from existing health projects. $3.1 billion (22.4$2.4 billion (17.9%) was for supply chain and logistics. Only $714.4 million (7.7$1519 (1448-1591) per person in 2050, although spending across countries is expected to remain varied. Interpretation Global health spending is expected to continue to grow, but remain unequally distributed between countries. We estimate that development organisations substantially increased the amount of development assistance for health provided in 2020. Continued efforts are needed to raise sufficient resources to mitigate the pandemic for the most vulnerable, and to help curtail the pandemic for all. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.Peer reviewe

Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17 : analysis for the Global Burden of Disease Study 2017

Background Across low-income and middle-income countries (LMICs), one in ten deaths in children younger than 5 years is attributable to diarrhoea. The substantial between-country variation in both diarrhoea incidence and mortality is attributable to interventions that protect children, prevent infection, and treat disease. Identifying subnational regions with the highest burden and mapping associated risk factors can aid in reducing preventable childhood diarrhoea. Methods We used Bayesian model-based geostatistics and a geolocated dataset comprising 15 072 746 children younger than 5 years from 466 surveys in 94 LMICs, in combination with findings of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, to estimate posterior distributions of diarrhoea prevalence, incidence, and mortality from 2000 to 2017. From these data, we estimated the burden of diarrhoea at varying subnational levels (termed units) by spatially aggregating draws, and we investigated the drivers of subnational patterns by creating aggregated risk factor estimates. Findings The greatest declines in diarrhoeal mortality were seen in south and southeast Asia and South America, where 54·0% (95% uncertainty interval [UI] 38·1–65·8), 17·4% (7·7–28·4), and 59·5% (34·2–86·9) of units, respectively, recorded decreases in deaths from diarrhoea greater than 10%. Although children in much of Africa remain at high risk of death due to diarrhoea, regions with the most deaths were outside Africa, with the highest mortality units located in Pakistan. Indonesia showed the greatest within-country geographical inequality; some regions had mortality rates nearly four times the average country rate. Reductions in mortality were correlated to improvements in water, sanitation, and hygiene (WASH) or reductions in child growth failure (CGF). Similarly, most high-risk areas had poor WASH, high CGF, or low oral rehydration therapy coverage. Interpretation By co-analysing geospatial trends in diarrhoeal burden and its key risk factors, we could assess candidate drivers of subnational death reduction. Further, by doing a counterfactual analysis of the remaining disease burden using key risk factors, we identified potential intervention strategies for vulnerable populations. In view of the demands for limited resources in LMICs, accurately quantifying the burden of diarrhoea and its drivers is important for precision public health

Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018

Anemia is a globally widespread condition in women and is associated with reduced economic productivity and increased mortality worldwide. Here we map annual 2000–2018 geospatial estimates of anemia prevalence in women of reproductive age (15–49 years) across 82 low- and middle-income countries (LMICs), stratify anemia by severity and aggregate results to policy-relevant administrative and national levels. Additionally, we provide subnational disparity analyses to provide a comprehensive overview of anemia prevalence inequalities within these countries and predict progress toward the World Health Organization’s Global Nutrition Target (WHO GNT) to reduce anemia by half by 2030. Our results demonstrate widespread moderate improvements in overall anemia prevalence but identify only three LMICs with a high probability of achieving the WHO GNT by 2030 at a national scale, and no LMIC is expected to achieve the target in all their subnational administrative units. Our maps show where large within-country disparities occur, as well as areas likely to fall short of the WHO GNT, offering precision public health tools so that adequate resource allocation and subsequent interventions can be targeted to the most vulnerable populations.Peer reviewe